An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Haemodialysis Patients With Uraemic Pruritus
Phase of Trial: Phase II/III
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Nalbuphine (Primary)
- Indications Pruritus
- Focus Adverse reactions
- Sponsors Trevi Therapeutics
- 18 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 14 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.